Content area

|
|

Testosteronsubstitutionsbehandling af hypogonadisme hos mænd med prostatacancer

Testosteronsubstitution til mænd, der tidligere er behandlet for prostatacancer, bør foregå i samarbejde med en urolog og kun efter grundig information om fordele og risici ved behandlingen.
Forfattere
Christian F.S. Jensen1, Mikkel Fode1, 2, Peter Østergren1 & Jens Sønksen1 1) Urologisk Afdeling, Herlev og Gentofte Hospital 2) Urologisk Afdeling, Sjællands Universitetshospital, Roskilde Ugeskr Læger 2017;179:V10160711
Reference: 
Ugeskr Læger 2017;179:V10160711
Blad nummer: 
Sidetal: 
2-6
Testosterone replacement therapy for hypogonadism in men with prostate cancer
Hypogonadism and prostate cancer (PCa) often coincide with increasing age. Recent reviews have found no evidence to suggest an increased risk of developing PCa with testosterone replacement therapy (TRT). The same lack of PCa risk is found in studies looking at men receiving TRT after radical prostatectomy for PCa. Reports on TRT in men on active surveillance are very few. In summary, current evidence does not support an association between TRT and an increased risk of PCa. Nevertheless, sufficiently powered trials with longer follow-up are warranted before making final conclusions.

💬 1 Kommentarer

Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Connie Lærkholm Hansen | 17/07
33 kommentarer
af Bente Lützen | 16/07
1 Kommentar
af Christian Frøkjær Thomsen | 16/07
1 Kommentar
af Klaus Roelsgaard | 15/07
2 kommentarer
af Geske Johanne Glahn | 14/07
1 Kommentar
af Finn Redke | 14/07
4 kommentarer
af Finn Redke | 14/07
3 kommentarer